SlideShare a Scribd company logo
2
Most read
3
Most read
4
Most read
Tech Note
Millipak®
Final Fill Filters Reduce
Contamination Risks and Simplify Filtration
System Design and Operation
Introduction
Final sterile filtration of parenteral drugs is a key step
in assuring microbial integrity of the drug product
and is often performed in single-use assemblies. Both
final filtration operations, and single-use assemblies
in general, are the focus of extensive regulatory
guidance and industry interest around practices that
assure sterility of the flow path and compatibility of the
assembly components with the process fluid.
It is a regulatory expectation that all sterilizing-
grade filters are integrity tested after use to confirm
the filter has the expected microbial retention
performance [1]. In addition to post-use testing,
some guidance documents state that ‘the integrity
of sterilized filter should be verified before use’
[2, 3]. In assemblies containing redundant filters,
performing pre-use, post-sterilization integrity testing
(PUPSIT) without compromising the aseptic flow path,
can be challenging. Reducing the risk of flow path
contamination was a driver for the redesigned port
on Millipak®
Final Fill filters. The port replaces the
traditional filter vent and provides an aseptic barrier
between the environment and process fluid.
This tech note summarizes the results of microbial
challenge studies that confirm the aseptic multi-
purpose port (AMPP) prevents microbial contamination
entering the flow path. We also show how these results
can be leveraged to simplify integrity testing and
product recovery following sterile filtration operations.
Confirming the Aseptic Flow Path
The AMPP contains three O-rings designed to form a
barrier between the outside air and the aseptic liquid
flow path, Figure 1. If air can move from the outside
to the liquid flow path, there is a potential risk of flow
path contamination. Conversely, if materials can move
from the flow path to the outside air, there is a risk
of exposing operators and environment to the drug
product.
Figure 2 illustrates the microbial challenge testing
strategy to confirm AMPP performance. No microbial
growth was detected in samples collected from any of
the treated capsules, confirming the AMPP provides a
barrier preventing bacteria from entering the flow path.
Importantly, as testing included gamma irradiation,
autoclaving under high stress temperature conditions,
and multiple actuations of the port, the results show
that rigorous filter set-up and use operations do not
compromise this barrier. These results confirm the
redesigned port can reduce contamination risk in
filtration operations, while protecting operators and the
filling environment from potential exposure to the drug
product.
Aseptic
Area
Product
Outside
Air
Aseptic
Area
Outside
Air
Figure 1. Schematic of AMPP on Millipak®
Final Fill Filter showing
different zones and key elements for maintaining an aseptic flow path.
The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.
2
Microbial Challenge Test Methods
To assess the capability of the AMPP for preventing microbial contamination, challenge testing was
performed with Brevundimonas diminuta (ATCC®
19146), the standard test organism used for sterilizing-
grade filter retention testing1
, Figure 2.
Preliminary tests confirmed low levels of microorganisms (≤ 10 colony forming units (cfu)) could be
recovered in 15 mL of Tryptic Soy Broth (TSB), and that low levels of inoculum (≤ 10 cfu) could be
recovered after at least 2 hours exposure to filters. Microorganism recovery was confirmed by turbidity and
microbial identification within 7 days.
All challenge tests included positive and negative controls.
•	Positive controls comprised an AMPP without O-rings from which ≤ 10 cfu B. diminuta was recovered.
•	Negative controls confirmed testing could be performed aseptically: no microbial challenge in the cam
slot, the AMPP was actuated 18 times and no turbidity was observed in the TSB flush.
For each challenge test, at least 107
cfu of B. diminuta1
was inoculated into the AMPP cam slot. Following
exposure, 15 mL of TSB was flushed through the capsule inlet and out through the AMPP, then incubated
at 30 ºC for 7 days before assessing turbidity. All tests and controls were run in triplicate. Two types of test
articles were assessed:
•	Gamma treatment: devices were subjected to gamma irradiation at 25-40 kGy then challenged with
≥107
cfu of B. diminuta.
•	Gamma-autoclave treatment: devices were subjected to gamma irradiation at 25-40 kGy, at least three
autoclave cycles at 126 °C for 90 minutes, then challenged with ≥107
cfu of B. diminuta before actuation
of the AMPP at least 18 times.
Figure 2. Summary of tests to evaluate
integrity of AMPP for maintaining a barrier
between air and flow path. Gamma treatment
(N=3)
25-40 kGy
Gamma-autoclave treatment
(N=3)
25-40 kGy;
Autoclave 126 ºC 3X
Flush devices
through AMPP
Assess for growth
after 7 day incubation
Actuate AMPP ≥ 18 times
Wiper O-rings
Aseptic
Area
Outside
Air
Challenge with 107
cfu B. diminuta
3
Simplified Integrity Testing and Filtration System Operation
The AMPP’s assured aseptic barrier allows operations
such as air flow into the filter capsule through an open
vent port without increasing risk of contamination.
This provides the opportunity for simpler and shorter
assembly designs.
For typical filter integrity tests through the filter inlet,
a tee with a vent filter and clamp are positioned
upstream of the sterilizing filter, isolating the filter
from wetting fluid. A second tube clamp isolates the
filter from the air-line connection, Figure 3A. Figure
3B highlights the simplified filtration system design for
filter integrity testing through the AMPP. A single line
connects the wetting fluid to the filter, and the air-line
connection is through the AMPP. This configuration
eliminates both the second tube clamp and 3-point
connection tee, simplifying the filtration system.
Filter integrity can also be confirmed by air diffusion
testing, however this should always be performed
with a direct air connection to the filter inlet, unless
additional process and test qualification is performed.
Figure 3: Configuration for connecting automated integrity testing instruments to sterilizing filters -
A: connection through the filter inlet, B: connection through the AMPP on Millipak®
Final Fill filters.
A B
Clamp
Clamp
Automated
Integrity Tester
Gas Filter
Sterilizing Filter
Automated
Integrity Tester
Clamp
Gas Filter
Sterilizing Filter
Figure 4 shows the results of integrity tests through
the AMPP and the filter inlet using an automated
Integritest®
instrument. The bubble point (BP)
specification for Durapore®
0.22 µm sterilizing-
grade membrane at 23 ºC is ≥ 50 psi. Bubble point
measurements through both the filter inlet and AMPP
met this specification, confirming the AMPP can be used
to assess filter integrity.
Together with the results of microbial challenge
testing, these results provide manufacturers with a
secure option for reducing contamination risk during
integrity testing, particularly during PUPSIT. In addition
to reduced contamination risks, the AMPP offers
opportunities for a simpler and shorter filtration system
design.
Figure 4: Bubble point results of Durapore®
0.22 µm sterilizing-grade
membrane following integrity testing through the Millipak®
Final Fill
filter inlet and AMPP using an automated Integritest®
instrument.
50
51
52
53
54
55
Inlet AMPP
BubblePoint(psi)
Set up
4
After processing fluid through sterilizing-grade filters,
some manufacturers may perform additional steps to
improve product recovery. These might include draining
by gravity, using a pump to recover hold-up on the
upstream side of the filter, or blowing-down the filter
with air.
Blowing-down a filter with air maximizes product
recovery as compared to other draining methods,
which can translate to substantial economic benefits,
particularly for high-value parenteral products. Millipak®
Final Fill filters can be blown-down through the filter
inlet [4], similar to traditional sterilizing filters, or
through the AMPP, which maintains an aseptic barrier.
Figure 5 shows the hold-up volumes of Millipak®
Final
Fill 200 filters following different draining and blow-
down procedures.
Hold-up volume of product in the filter is reduced by
implementing a blow-down as compared to gravity
draining alone. The minimum hold-up volume was
achieved when the filter was subjected to a pressure
hold at 70 psig applied through either the filter inlet
or the AMPP. Running a bubble point integrity test
on the filter through the AMPP reduced hold-up as
compared to gravity drain but resulted in more liquid
being retained in the filter as compared to the higher
pressure conditions of 70 psig.
Methods for Determining Filter
Hold-up Volume
Hold-up volume of Millipak®
Final Fill 200 filters
containing Durapore®
0.22 µm membrane was
determined after different methods of filter
draining or blow-down. Hold-up volume was the
difference in filter weight after draining or blow-
down and the dry weight of the filters (with no
fittings).
Hold-up volume following draining by gravity
was determined by filling the upstream and
downstream sides of the filter with water, then
opening the outlet and allowing liquid upstream
and downstream of the filter to drain. The
hold-up volume following inlet blow-down was
determined by connecting an air source to the
inlet of prewetted filters and applying pressure
to 70 psig for one minute, 20 psi above the
membrane’s bubble point specification. Blow-
down through the AMPP was performed in two
ways: the first involved connecting an automated
Integritest®
instrument to the AMPP with tubing
and running a pressure hold routine (70 psig
for 1 minute), similar to the inlet blow-down
described above. The second involved using an
automated Integritest®
instrument to increase
pressure to the membrane bubble point of
≥50 psi.
Increase Product Recovery with Filter Blow-down
Figure 5. Mean hold-up volume of Millipak®
Final Fill 200 filters
containing sterilizing grade Durapore®
0.22 µm membrane after
different drain or blow-down methods. Each value represents the
mean and standard deviation from three replicate filters.
0
10
20
30
40
50
60
70
Blow-down Method
Hold-upvolume(mL)
Hold up of Millipak®
Final Fill 200 Filters
Following Blow-down
Gravity Drain
Pressure increase to membrane BP through AMPP
Presssure through inlet to 20 psi above BP for 1 min
Pressure through AMPP to 20 psi above BP for 1 min
Importantly, using the AMPP, rather than the filter
inlet to perform blow-down offers advantages. Firstly,
the automated Integritest®
instrument can be directly
connected to the AMPP, eliminating the need to
switch to a controlled pressurized gas source which
streamlines integrity testing and product recovery.
Secondly, using the AMPP reduces the number of
connections and removes the need for a tee connector
and clamp, minimizing contamination risks while
simplifying operations.
Conclusions
Our results demonstrate that the aseptic multi-
purpose port on Millipak®
Final Fill capsule filters
protects the aseptic flow path and maintains a barrier
to the environment, even after multiple actuations.
Leveraging this protection, an automated Integritest®
instrument tester can be connected to this port to
simplify both integrity testing, especially PUPSIT,
and product recovery while minimizing the risk of
introducing microbial contaminants into the flow path.
© 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Millipore, Millipak,
Durapore, and Integritest are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of
their respective owners. Detailed information on trademarks is available via publicly accessible resources.
Lit. No. MS_TN4709EN Ver. 1.0
2019-25248
12/2019
To Place an Order or Receive Technical Assistance
Please visit EMDMillipore.com/contactPS
For additional information, please visit EMDMillipore.com
MilliporeSigma
400 Summit Drive
Burlington, MA 01803
References:
1.	FDA. Guidance for Industry Sterile Drug Products Produced by
Aseptic Processing - Current Good Manufacturing Practice. 2004;
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070342.pdf.
2.	European Commission. EU Guidelines to Good Manufacturing Practice
Medicinal Products for Human and Veterinary Use. 2008;
http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm,
3.	European Agency for the Evaluation of Medicinal Products. Note for
Guidance on Manufacture of the Finished Dosage Form. 1996;
http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500002916.pdf.
4.	 Improve Product Recovery Using Blow-down and Millipak®
Final Fill
Filters. Lit No. MS_TB4382EN

More Related Content

PDF
White Paper: Explore Versatility with SPTFF
PDF
Improve Process Efficiency in Bioprocess Streams by Prefiltration Optimizatio...
PDF
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
PDF
Reducing Contamination Risk and Improving Product Recovery During Final Steri...
PPTX
Cleaning validation
PPSX
Good containment practices
PDF
A hands on guide to ultrafiltration1
PPTX
qualification of Hptlc
White Paper: Explore Versatility with SPTFF
Improve Process Efficiency in Bioprocess Streams by Prefiltration Optimizatio...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Reducing Contamination Risk and Improving Product Recovery During Final Steri...
Cleaning validation
Good containment practices
A hands on guide to ultrafiltration1
qualification of Hptlc

What's hot (20)

PPTX
Environmental monitoring
PDF
Selection, sizing, and operation of bioprocess filtration trains for optimal ...
PDF
Normal Flow Filtration: Design and Scale Up
PPT
Basic Concepts of Cleaning validation
PDF
Stopper Processing
PDF
Stopper Siliconization
PDF
Pharmaceutical Engineering Downflow Booth Testing
PPTX
Cleaning validation
PPTX
PROCESS VALIDATION for Sem Solid
PPT
cleaning validation..
PPTX
Cleaning validation strategy & regulations
PDF
Microbiological Environmental Monitoring in Pharmaceutical Facility
PDF
Inline Flocculation for Harvest and Perfusate Clarification
PDF
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
PPTX
Cleaning validation
PDF
1. cleaning validation basic concept
PPT
ENVIRONMENTAL MONITORING
PPTX
Cleaning Validation by- Deepak Kumar.
PPT
Filter validation
PPTX
IPQC Test for Liquid Dosage Forms
Environmental monitoring
Selection, sizing, and operation of bioprocess filtration trains for optimal ...
Normal Flow Filtration: Design and Scale Up
Basic Concepts of Cleaning validation
Stopper Processing
Stopper Siliconization
Pharmaceutical Engineering Downflow Booth Testing
Cleaning validation
PROCESS VALIDATION for Sem Solid
cleaning validation..
Cleaning validation strategy & regulations
Microbiological Environmental Monitoring in Pharmaceutical Facility
Inline Flocculation for Harvest and Perfusate Clarification
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Cleaning validation
1. cleaning validation basic concept
ENVIRONMENTAL MONITORING
Cleaning Validation by- Deepak Kumar.
Filter validation
IPQC Test for Liquid Dosage Forms
Ad

Similar to Millipak® Final Fill Filters Reduce Contamination Risks and Simplify Filtration System Design and Operation (20)

PDF
Reducing Contamination Risk and Improving Product Recovery During Final Steri...
PDF
Redesigned Filter Capsule Improves Final Filtration Assembly Design and Opera...
PDF
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
PPT
Filter validation
PPTX
Millipak Final Fill Filtration Presentation
PDF
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
PDF
Millipak® Final Fill Filters
PDF
TESTING AND COMPARISON OF THE FILTERSAFE STANDARD, TURBO AND SUPERTURBO CONFI...
PDF
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
PDF
2008 11 25_gmp-an1_en
PDF
Pellicon 2
PDF
Potential Impact of Draft Annex 1 on Sterilizing Filtration
PDF
Care and use manual waters x bridge columns
DOC
reliability tests for lungs
PPTX
66 membrane filter integrity test
PDF
Selection, sizing, and operation of bioprocess filtration trains for optimal ...
PDF
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
PDF
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
DOCX
Phụ lục 6. Tiêu chuẩn GMP WHO cho chế phẩm vô trùng
Reducing Contamination Risk and Improving Product Recovery During Final Steri...
Redesigned Filter Capsule Improves Final Filtration Assembly Design and Opera...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filter validation
Millipak Final Fill Filtration Presentation
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Millipak® Final Fill Filters
TESTING AND COMPARISON OF THE FILTERSAFE STANDARD, TURBO AND SUPERTURBO CONFI...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
2008 11 25_gmp-an1_en
Pellicon 2
Potential Impact of Draft Annex 1 on Sterilizing Filtration
Care and use manual waters x bridge columns
reliability tests for lungs
66 membrane filter integrity test
Selection, sizing, and operation of bioprocess filtration trains for optimal ...
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
Phụ lục 6. Tiêu chuẩn GMP WHO cho chế phẩm vô trùng
Ad

More from MilliporeSigma (20)

PDF
Launch of our new Titanium Dioxide Alternative
PDF
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
PDF
Use of Excipients in Downstream Processing to Improve Protein Purification
PDF
Exploring the protein stabilizing capability of surfactants against agitation...
PDF
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
PDF
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
PDF
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
PDF
The Future of Pharma- and Biopharmaceutical Audits
PDF
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
PDF
Identity testing by NGS as a means of risk mitigation for viral gene therapies
PDF
Latest advancements of melt based 3D printing technologies for oral drug deli...
PDF
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
PDF
How does the ICH Q5A revision impact viral safety strategies for biologics?
PDF
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
PDF
Insights from a Global Collaboration Accelerating Vaccine Development with an...
PDF
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
PDF
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
PDF
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
PDF
The Developability Classification System (DCS): Enabling an Optimized Approac...
PDF
How to Accelerate and Enhance ADC Therapies
Launch of our new Titanium Dioxide Alternative
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
Use of Excipients in Downstream Processing to Improve Protein Purification
Exploring the protein stabilizing capability of surfactants against agitation...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Future of Pharma- and Biopharmaceutical Audits
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Latest advancements of melt based 3D printing technologies for oral drug deli...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
How does the ICH Q5A revision impact viral safety strategies for biologics?
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The Developability Classification System (DCS): Enabling an Optimized Approac...
How to Accelerate and Enhance ADC Therapies

Recently uploaded (20)

DOCX
Copies if quanti.docxsegdfhfkhjhlkjlj,klkj
PPTX
Galactosemia pathophysiology, clinical features, investigation and treatment ...
PDF
MINERAL & VITAMIN CHARTS fggfdtujhfd.pdf
PPT
Microscope is an instrument that makes an enlarged image of a small object, t...
PPTX
PE and Health 7 Quarter 3 Lesson 1 Day 3,4 and 5.pptx
PPT
KULIAH UG WANITA Prof Endang 121110 (1).ppt
PPTX
Pulmonary Circulation PPT final for easy
PDF
NUTRITION THROUGHOUT THE LIFE CYCLE CHILDHOOD -AGEING
PDF
CHAPTER 9 MEETING SAFETY NEEDS FOR OLDER ADULTS.pdf
PPT
Parental-Carer-mental-illness-and-Potential-impact-on-Dependant-Children.ppt
PPTX
AI_in_Pharmaceutical_Technology_Presentation.pptx
PPTX
NUTRITIONAL PROBLEMS, CHANGES NEEDED TO PREVENT MALNUTRITION
PDF
Khaled Sary- Trailblazers of Transformation Middle East's 5 Most Inspiring Le...
PPTX
CBT FOR OCD TREATMENT WITHOUT MEDICATION
PPTX
COMMUNICATION SKILSS IN NURSING PRACTICE
PPTX
Current Treatment Of Heart Failure By Dr Masood Ahmed
PPTX
Importance of Immediate Response (1).pptx
PPTX
Rheumatic heart diseases with Type 2 Diabetes Mellitus
PDF
Megan Miller Colona Illinois - Passionate About CrossFit
PPTX
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
Copies if quanti.docxsegdfhfkhjhlkjlj,klkj
Galactosemia pathophysiology, clinical features, investigation and treatment ...
MINERAL & VITAMIN CHARTS fggfdtujhfd.pdf
Microscope is an instrument that makes an enlarged image of a small object, t...
PE and Health 7 Quarter 3 Lesson 1 Day 3,4 and 5.pptx
KULIAH UG WANITA Prof Endang 121110 (1).ppt
Pulmonary Circulation PPT final for easy
NUTRITION THROUGHOUT THE LIFE CYCLE CHILDHOOD -AGEING
CHAPTER 9 MEETING SAFETY NEEDS FOR OLDER ADULTS.pdf
Parental-Carer-mental-illness-and-Potential-impact-on-Dependant-Children.ppt
AI_in_Pharmaceutical_Technology_Presentation.pptx
NUTRITIONAL PROBLEMS, CHANGES NEEDED TO PREVENT MALNUTRITION
Khaled Sary- Trailblazers of Transformation Middle East's 5 Most Inspiring Le...
CBT FOR OCD TREATMENT WITHOUT MEDICATION
COMMUNICATION SKILSS IN NURSING PRACTICE
Current Treatment Of Heart Failure By Dr Masood Ahmed
Importance of Immediate Response (1).pptx
Rheumatic heart diseases with Type 2 Diabetes Mellitus
Megan Miller Colona Illinois - Passionate About CrossFit
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...

Millipak® Final Fill Filters Reduce Contamination Risks and Simplify Filtration System Design and Operation

  • 1. Tech Note Millipak® Final Fill Filters Reduce Contamination Risks and Simplify Filtration System Design and Operation Introduction Final sterile filtration of parenteral drugs is a key step in assuring microbial integrity of the drug product and is often performed in single-use assemblies. Both final filtration operations, and single-use assemblies in general, are the focus of extensive regulatory guidance and industry interest around practices that assure sterility of the flow path and compatibility of the assembly components with the process fluid. It is a regulatory expectation that all sterilizing- grade filters are integrity tested after use to confirm the filter has the expected microbial retention performance [1]. In addition to post-use testing, some guidance documents state that ‘the integrity of sterilized filter should be verified before use’ [2, 3]. In assemblies containing redundant filters, performing pre-use, post-sterilization integrity testing (PUPSIT) without compromising the aseptic flow path, can be challenging. Reducing the risk of flow path contamination was a driver for the redesigned port on Millipak® Final Fill filters. The port replaces the traditional filter vent and provides an aseptic barrier between the environment and process fluid. This tech note summarizes the results of microbial challenge studies that confirm the aseptic multi- purpose port (AMPP) prevents microbial contamination entering the flow path. We also show how these results can be leveraged to simplify integrity testing and product recovery following sterile filtration operations. Confirming the Aseptic Flow Path The AMPP contains three O-rings designed to form a barrier between the outside air and the aseptic liquid flow path, Figure 1. If air can move from the outside to the liquid flow path, there is a potential risk of flow path contamination. Conversely, if materials can move from the flow path to the outside air, there is a risk of exposing operators and environment to the drug product. Figure 2 illustrates the microbial challenge testing strategy to confirm AMPP performance. No microbial growth was detected in samples collected from any of the treated capsules, confirming the AMPP provides a barrier preventing bacteria from entering the flow path. Importantly, as testing included gamma irradiation, autoclaving under high stress temperature conditions, and multiple actuations of the port, the results show that rigorous filter set-up and use operations do not compromise this barrier. These results confirm the redesigned port can reduce contamination risk in filtration operations, while protecting operators and the filling environment from potential exposure to the drug product. Aseptic Area Product Outside Air Aseptic Area Outside Air Figure 1. Schematic of AMPP on Millipak® Final Fill Filter showing different zones and key elements for maintaining an aseptic flow path. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
  • 2. 2 Microbial Challenge Test Methods To assess the capability of the AMPP for preventing microbial contamination, challenge testing was performed with Brevundimonas diminuta (ATCC® 19146), the standard test organism used for sterilizing- grade filter retention testing1 , Figure 2. Preliminary tests confirmed low levels of microorganisms (≤ 10 colony forming units (cfu)) could be recovered in 15 mL of Tryptic Soy Broth (TSB), and that low levels of inoculum (≤ 10 cfu) could be recovered after at least 2 hours exposure to filters. Microorganism recovery was confirmed by turbidity and microbial identification within 7 days. All challenge tests included positive and negative controls. • Positive controls comprised an AMPP without O-rings from which ≤ 10 cfu B. diminuta was recovered. • Negative controls confirmed testing could be performed aseptically: no microbial challenge in the cam slot, the AMPP was actuated 18 times and no turbidity was observed in the TSB flush. For each challenge test, at least 107 cfu of B. diminuta1 was inoculated into the AMPP cam slot. Following exposure, 15 mL of TSB was flushed through the capsule inlet and out through the AMPP, then incubated at 30 ºC for 7 days before assessing turbidity. All tests and controls were run in triplicate. Two types of test articles were assessed: • Gamma treatment: devices were subjected to gamma irradiation at 25-40 kGy then challenged with ≥107 cfu of B. diminuta. • Gamma-autoclave treatment: devices were subjected to gamma irradiation at 25-40 kGy, at least three autoclave cycles at 126 °C for 90 minutes, then challenged with ≥107 cfu of B. diminuta before actuation of the AMPP at least 18 times. Figure 2. Summary of tests to evaluate integrity of AMPP for maintaining a barrier between air and flow path. Gamma treatment (N=3) 25-40 kGy Gamma-autoclave treatment (N=3) 25-40 kGy; Autoclave 126 ºC 3X Flush devices through AMPP Assess for growth after 7 day incubation Actuate AMPP ≥ 18 times Wiper O-rings Aseptic Area Outside Air Challenge with 107 cfu B. diminuta
  • 3. 3 Simplified Integrity Testing and Filtration System Operation The AMPP’s assured aseptic barrier allows operations such as air flow into the filter capsule through an open vent port without increasing risk of contamination. This provides the opportunity for simpler and shorter assembly designs. For typical filter integrity tests through the filter inlet, a tee with a vent filter and clamp are positioned upstream of the sterilizing filter, isolating the filter from wetting fluid. A second tube clamp isolates the filter from the air-line connection, Figure 3A. Figure 3B highlights the simplified filtration system design for filter integrity testing through the AMPP. A single line connects the wetting fluid to the filter, and the air-line connection is through the AMPP. This configuration eliminates both the second tube clamp and 3-point connection tee, simplifying the filtration system. Filter integrity can also be confirmed by air diffusion testing, however this should always be performed with a direct air connection to the filter inlet, unless additional process and test qualification is performed. Figure 3: Configuration for connecting automated integrity testing instruments to sterilizing filters - A: connection through the filter inlet, B: connection through the AMPP on Millipak® Final Fill filters. A B Clamp Clamp Automated Integrity Tester Gas Filter Sterilizing Filter Automated Integrity Tester Clamp Gas Filter Sterilizing Filter Figure 4 shows the results of integrity tests through the AMPP and the filter inlet using an automated Integritest® instrument. The bubble point (BP) specification for Durapore® 0.22 µm sterilizing- grade membrane at 23 ºC is ≥ 50 psi. Bubble point measurements through both the filter inlet and AMPP met this specification, confirming the AMPP can be used to assess filter integrity. Together with the results of microbial challenge testing, these results provide manufacturers with a secure option for reducing contamination risk during integrity testing, particularly during PUPSIT. In addition to reduced contamination risks, the AMPP offers opportunities for a simpler and shorter filtration system design. Figure 4: Bubble point results of Durapore® 0.22 µm sterilizing-grade membrane following integrity testing through the Millipak® Final Fill filter inlet and AMPP using an automated Integritest® instrument. 50 51 52 53 54 55 Inlet AMPP BubblePoint(psi) Set up
  • 4. 4 After processing fluid through sterilizing-grade filters, some manufacturers may perform additional steps to improve product recovery. These might include draining by gravity, using a pump to recover hold-up on the upstream side of the filter, or blowing-down the filter with air. Blowing-down a filter with air maximizes product recovery as compared to other draining methods, which can translate to substantial economic benefits, particularly for high-value parenteral products. Millipak® Final Fill filters can be blown-down through the filter inlet [4], similar to traditional sterilizing filters, or through the AMPP, which maintains an aseptic barrier. Figure 5 shows the hold-up volumes of Millipak® Final Fill 200 filters following different draining and blow- down procedures. Hold-up volume of product in the filter is reduced by implementing a blow-down as compared to gravity draining alone. The minimum hold-up volume was achieved when the filter was subjected to a pressure hold at 70 psig applied through either the filter inlet or the AMPP. Running a bubble point integrity test on the filter through the AMPP reduced hold-up as compared to gravity drain but resulted in more liquid being retained in the filter as compared to the higher pressure conditions of 70 psig. Methods for Determining Filter Hold-up Volume Hold-up volume of Millipak® Final Fill 200 filters containing Durapore® 0.22 µm membrane was determined after different methods of filter draining or blow-down. Hold-up volume was the difference in filter weight after draining or blow- down and the dry weight of the filters (with no fittings). Hold-up volume following draining by gravity was determined by filling the upstream and downstream sides of the filter with water, then opening the outlet and allowing liquid upstream and downstream of the filter to drain. The hold-up volume following inlet blow-down was determined by connecting an air source to the inlet of prewetted filters and applying pressure to 70 psig for one minute, 20 psi above the membrane’s bubble point specification. Blow- down through the AMPP was performed in two ways: the first involved connecting an automated Integritest® instrument to the AMPP with tubing and running a pressure hold routine (70 psig for 1 minute), similar to the inlet blow-down described above. The second involved using an automated Integritest® instrument to increase pressure to the membrane bubble point of ≥50 psi. Increase Product Recovery with Filter Blow-down Figure 5. Mean hold-up volume of Millipak® Final Fill 200 filters containing sterilizing grade Durapore® 0.22 µm membrane after different drain or blow-down methods. Each value represents the mean and standard deviation from three replicate filters. 0 10 20 30 40 50 60 70 Blow-down Method Hold-upvolume(mL) Hold up of Millipak® Final Fill 200 Filters Following Blow-down Gravity Drain Pressure increase to membrane BP through AMPP Presssure through inlet to 20 psi above BP for 1 min Pressure through AMPP to 20 psi above BP for 1 min Importantly, using the AMPP, rather than the filter inlet to perform blow-down offers advantages. Firstly, the automated Integritest® instrument can be directly connected to the AMPP, eliminating the need to switch to a controlled pressurized gas source which streamlines integrity testing and product recovery. Secondly, using the AMPP reduces the number of connections and removes the need for a tee connector and clamp, minimizing contamination risks while simplifying operations. Conclusions Our results demonstrate that the aseptic multi- purpose port on Millipak® Final Fill capsule filters protects the aseptic flow path and maintains a barrier to the environment, even after multiple actuations. Leveraging this protection, an automated Integritest® instrument tester can be connected to this port to simplify both integrity testing, especially PUPSIT, and product recovery while minimizing the risk of introducing microbial contaminants into the flow path.
  • 5. © 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Millipore, Millipak, Durapore, and Integritest are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Lit. No. MS_TN4709EN Ver. 1.0 2019-25248 12/2019 To Place an Order or Receive Technical Assistance Please visit EMDMillipore.com/contactPS For additional information, please visit EMDMillipore.com MilliporeSigma 400 Summit Drive Burlington, MA 01803 References: 1. FDA. Guidance for Industry Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice. 2004; http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070342.pdf. 2. European Commission. EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. 2008; http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm, 3. European Agency for the Evaluation of Medicinal Products. Note for Guidance on Manufacture of the Finished Dosage Form. 1996; http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500002916.pdf. 4. Improve Product Recovery Using Blow-down and Millipak® Final Fill Filters. Lit No. MS_TB4382EN